ArticlePloS one2015
Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Cardiovascular disease in idiopathic pulmonary fibrosis: a systematic review and meta-analysis of observational studies.Frontiers in medicine · 2025Pooled it
- Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.Thorax · 2017Trial
- Combining Geriatric Nutritional Risk Index with Total Cholesterol to Predict Pneumonia Mortality Risks in a Cohort of General Older Adults.Nutrients · 2026Article
- Association between statin use and the risk for idiopathic pulmonary fibrosis and its prognosis: a nationwide, population-based study.Scientific reports · 2024Article
- A Step towards understanding coronary artery disease: a complication in idiopathic pulmonary fibrosis.BMJ open respiratory research · 2024Article
- Article
- Effect of Statins on All-Cause Mortality in Adults: A Systematic Review and Meta-Analysis of Propensity Score-Matched Studies.Journal of clinical medicine · 2022Review
- Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis.Oxidative medicine and cellular longevity · 2022Review
- LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis.Clinical and translational medicine · 2022Article
- Article
- Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients.Translational medicine communications · 2021Article
- The Effect of Cardiovascular Medications on Disease-Related Outcomes in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2021Review
- Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?American heart journal · 2020Review
- Screening for YAP Inhibitors Identifies Statins as Modulators of Fibrosis.American journal of respiratory cell and molecular biology · 2020Article
- The therapy of idiopathic pulmonary fibrosis: what is next?European respiratory review : an official journal of the European Respiratory Society · 2019Review
- Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management.Advances in therapy · 2019Review
- LXR/RXR pathway signaling associated with triple-negative breast cancer in African American women.Breast cancer (Dove Medical Press) · 2019Article
- Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases - a claims data analysis.Respiratory research · 2018Article
- Article
- Statins as anti-inflammatory agents: A potential therapeutic role in sight-threatening non-infectious uveitis.Porto biomedical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe hypothesized that statin use begun before the diagnosis of interstitial lung disease is associated with reduced mortality.
methodsWe studied all patients diagnosed with interstitial lung disease in the entire Danish population from 1995 through 2009, comparing statin use versus no statin use in a nested 1:2 matched study.
resultsThe cumulative survival as a function of follow-up time from the date of diagnosis of interstitial lung disease (n = 1,786 + 3,572) and idiopathic lung fibrosis (n = 261 + 522) was higher for statin users versus never users (log-rank: P = 7 · 10(-9) and P = 0.05). The median survival time in patients with interstitial lung disease was 3.3 years in statin users and 2.1 years in never users. Corresponding values in patients with idiopathic lung fibrosis were 3.4 versus 2.4 years. After multivariable adjustment, the hazard ratio for all-cause mortality for statin users versus never users was 0.73 (95% confidence interval, 0.68 to 0.79) in patients with interstitial lung disease and 0.76 (0.62 to 0.93) in patients with idiopathic lung fibrosis. Results were robust in all sensitivity analyses.
conclusionAmong patients with interstitial lung disease statin use was associated with reduced all-cause mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.